Compare Neurocrine Biosciences Inc (NBIX) vs Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 (SLVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 — how do they compare? Neurocrine Biosciences Inc trades at $142.6 (market cap $14.36B), while Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 trades at $64.61 (market cap $394.18M). The key difference: Neurocrine Biosciences Inc is far larger — about 36.4× Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 for 63 Days on average.
| NBIX | SLVO | |
|---|---|---|
Market Cap | $14.36B | $394.18M |
Volume | 1,237,180 | 84,843 |
Sector | Health | Income / Options Overlay |
52-Week High | $185.50 | $107.41 |
52-Week Low | $123.10 | $61.81 |
Typical Hold Time | 23 Days | 63 Days |
Enterprise Value | $14.37B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
SLVO is trading at $63.56, down 2.67% amid bearish technical signals. The stock recently crossed below its 50-day moving average of $73.20, indicating weakening momentum. Recent news highlights silver price declines and technical breakdowns as key drivers. Technical indicators show a bearish moving average signal with neutral oscillators, while RSI levels near 29 suggest potential oversold conditions.
The outlook remains cautious with silver market volatility and dollar strength creating headwinds. Investment opportunity exists if oversold conditions lead to reversal, but risks include continued commodity pressure and technical breakdown. The stock faces resistance at $66-$67 levels with support around $64-$65.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033
SLVO is an exchange-traded note issued by UBS AG that provides investors with exposure to the performance of a silver-based covered call strategy. The ETN tracks the daily return of the ISE Enhanced 100x Leveraged Silver ETN Index, which combines a long position in silver with a covered call strategy on the silver position. This strategy aims to generate current income from the option premiums, which can provide a buffer during sideways or slightly down markets for silver, but it also caps the potential gains from a significant rise in silver prices. As an ETN, it is subject to the credit risk of the issuer, UBS AG, and has an expiration date of April 21, 2033.
Read more on SLVO →
